Conference on Retrovirus and Opportunistic Infections (CROI 2024), Denver, Colorado, USA, 3-6 March 2024.
Poster presentation:
Temporal Trends of Cardiovascular Disease Incidence in People with HIV from 2001-2021 presented by Nadine Jaschinski on behalf of the RESPOND Study Group.POSTER
Poster presentation:
Increased Cancer Risk With Low CD4 Counts Persists Despite Over 2 Years of Virological Suppression presented by Jennifer Hoy on behalf of the RESPOND Study Group.POSTER
The 25th International AIDS conference (IAS) 22-26 July 2024.
Oral presentation:
Detailed modeling of viremia exposure does not independently predict cardiovascular diseases in people with HIV, presented by Olof Elvstam on behalf of the RESPOND Study Group.PRESENTATION
Australasian HIV & AIDS conference (ASHM), Sydney, Australia, 16-18 September 2024.
Oral presentation:
Risk of cancer in people with HIV with poor immune recovery despite sustained virological suppression for more than two years on effective antiretroviral treatment, presented by Win Min Han on behalf of the RESPOND Study Group.PRESENTATION
HIV&Virology Nordic Conference, Stockholm, Sweden, 25-27 September 2024.
Poster presentation:
RESPONDing to Contemporary Challenges for People Living with HIV: An Envolving Cohort Collaboration, presented by Bastian Neesgaard on behalf of the RESPOND Study Group.POSTER
HIV Drug Therapy Glasgow 2024, Glasgow, Great Britain, 10-13 November 2024.
Accepted for poster presentation:
Outcomes after the most common cancers in people with HIV will be presented by Alisa Timiryasova on behalf of the RESPOND and D:A:D study groups.
Accepted for poster presentation:
Mortality using raltegravir versus other integrase inhibitors in people with HIV in Europe and Australia will be presented by Erich Tusch on behalf of the RESPOND study group.
Accepted for poster presentation:
Prevalence of HIV drug resistance in people newly diagnosed with HIV who have used pre-exposure prophylaxis in Europe: the PrEPaRE study, will be presented by Valentina Cambiano on behalf of the RESPOND study group.